For the first time in its history, the U.S. Food and Drug Administration (FDA) approved Botox, a potentially life-saving treatment for facial hair and acne.
The agency’s decision on Wednesday, following years of delay, came as President Donald Trump, who promised during the 2016 presidential campaign to “make America great again,” announced he would rescind the rule and approve the drug for people with facial hair problems.
Botox, an injectable drug, was first approved in the U.-S.
in 1996 and has been on the market since 2011.
The FDA is expected to approve the first-ever FDA-approved Botox application in 2019.
Under the law, a person can apply for Botox in person to receive the drug.
The drug has been available in the United States since 2008 and is used to treat conditions such as psoriasis and acne in adults.
According to a release from the FDA, people who have facial hair are more likely to suffer from psorosis and other skin problems and suffer more from acne and other conditions, including depression.
The release noted that Botox could be beneficial for people who suffer from facial hair loss due to aging, as well as those with conditions such to asthma and cardiovascular problems.
It also noted that the drug is effective in people who are unable to tolerate standard treatments, including injections.
The medication, which costs $75 a month for a six-pack of 15 mg doses, has been approved for the treatment of more than 50 million people worldwide, according to the FDA.